Skip to main content

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

HHS-NIH11 Posted PAR-25-321

Description

Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Eligibility

Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Funding Details
Award Floor
Not specified
Award Ceiling
Not specified
Total Estimated Funding
Not specified
Expected Awards
Not specified
Key Dates
Posted
December 10, 2024
Closes
January 7, 2028 652d
Archive Date
February 12, 2028
Agency Information
Agency Name
HHS-NIH11
Agency Code
HHS-NIH11
Funding Instrument
Other